Leading Beeline Medicines’ pipeline is afimetoran, which is in Phase 2 development for systemic lupus erythematosus with data ...

After revealing in February plans to save $2 billion more on top of a previously disclosed cost-cutting initiative, Bristol Myers Squibb is conducting another round of job cuts in the Garden State.

Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s ...

Upon Opdualag’s approval in 2022 as a first-in-class cancer immunotherapy, Bristol Myers Squibb was anxious to explore its potential in a variety of indications. But so far, the company is striking ...

Bristol-Myers Squibb (BMY) looks undervalued at 8.9x forward P/E; see growth catalysts, FDA/Phase 3 timelines, and a $68 ...

There are pharmaceutical companies that can fit into a value investor's portfolio. Broadly speaking, these companies look ...

US clinical-stage biotechnology company Beeline Medicines today announced its official debut with the mission of developing ...

Oxford BioTherapeutics has entered a multi‑year collaboration with Bristol Myers Squibb to discover and develop novel T‑cell ...

Bristol Myers Squibb & Co (NYSE:BMY) on Monday announced topline data from the Phase 3 ODYSSEY-HCM trial of Camzyos (mavacamten) for symptomatic New York Heart Association (NYHA) class II-III ...

On April 9, 2026, Oxford BioTherapeutics announced a multi-year collaboration with Bristol Myers Squibb focused on the discovery and development of T-cell engager therapies for solid tumors. 1 ...